Kamada discontinues Phase 3 inhaled AAT clinical trial

Kamada (KMDA) announced that the independent Data and Safety Monitoring Board advised the Company that, based on a prespecified interim futility analysis, the Phase 3 InnovAATe trial of Inhaled AAT for the treatment of Alpha-1 Antitrypsin Deficiency is unlikely to demonstrate a statistically significant benefit in its primary endpoint – lung function measured by FEV1. Based on the futility analysis outcome, the Company will discontinue the trial. The discontinuation is solely related to the low likelihood of a successful efficacy outcome and is not reflective of any safety concerns.